248. グルコーストランスポーター1欠損症 Disease details / Clinical trials / Drug dev / DR info /

臨床試験数 : 29 / 薬物数 : 9 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
GLUT1 DS   
   Institut National de la Santé Et de la Recherche Médicale, France
      2013   Phase 2   NCT02014883   France;
Ketoflo   
   Vitaflo International, Ltd
      2020   -   NCT04399954   United Kingdom;
Keyo   
   Vitaflo International, Ltd
      2016   -   NCT02915211   United Kingdom;
Krio   
   Vitaflo International, Ltd
      2018   -   NCT03202108   United Kingdom;
TRIHEPTANOINA   
   Ultragenyx Pharmaceutical Inc
      2017   Phase 2   EUCTR2015-000389-69-ES   Australia;Denmark;France;Israel;Italy;Spain;United Kingdom;United States;
Triheptanoin   
   Adrian Lacy
      2014   Phase 2   NCT02036853   United States;
   Jerry Vockley, MD, PhD
      2017   -   NCT02968953   United States;
   Juan Pascual
      2017   Phase 1   NCT03041363   United States;
      2015   Phase 1/Phase 2   NCT02021526   United States;
      2013   -   NCT02018302   United States;
      2012   Phase 1   NCT02018315   United States;
   Ultragenyx Pharmaceutical Inc
      2019   -   NCT03773770   -
      2017   Phase 2   EUCTR2015-000389-69-ES   Australia;Denmark;France;Israel;Italy;Spain;United Kingdom;United States;
   University of British Columbia
      2014   Phase 2   NCT02000960   Canada;
   University of Texas Southwestern Medical Center
      2018   Phase 2   NCT03301532   United States;
      2018   Phase 2   NCT03181399   United States;
Triheptanoin / Triheptanoina   
   Ultragenyx Pharmaceutical Inc
      2015   Phase 2   EUCTR2013-003771-35-ES   Denmark;France;Hungary;Italy;Spain;United Kingdom;United States;
UX007   
   Ultragenyx Pharmaceutical Inc
      2017   Phase 3   NCT02960217   France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005536-17-GB   Australia;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005536-17-FR   Australia;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005536-17-ES   Australia;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005536-17-DE   Australia;France;Germany;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-000389-69-GB   Australia;Denmark;France;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-000389-69-ES   Australia;Denmark;France;Israel;Italy;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-000389-69-DK   Australia;Denmark;Israel;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2013-003771-35-DK   Australia;Denmark;France;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2013-003771-35-HU   Australia;Denmark;France;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2015   Phase 2   NCT02599961   Australia;Denmark;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-003771-35-GB   Denmark;France;Hungary;Italy;Spain;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-003771-35-ES   Denmark;France;Hungary;Italy;Spain;United Kingdom;United States;
      2014   Phase 2   NCT01993186   Australia;France;Hungary;Israel;Italy;Spain;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003771-35-IT   Denmark;France;Hungary;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2013-003771-35-FR   Denmark;France;Hungary;Italy;Spain;United Kingdom;United States;